News & Updates

High potassium intake lowers CKD risk

22 Apr 2024

Individuals with a higher intake of potassium are less likely to develop chronic kidney disease (CKD), according to a population-based prospective study.

High potassium intake lowers CKD risk

22 Apr 2024

Real-world experience with CAR T-cell treatment of B-cell lymphomas

22 Apr 2024 by

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy and manageable toxicity and has evolved as a new standard of care (SoC) for relapsed/refractory (R/R) B-cell lymphomas. At a Novartis-sponsored meeting organized by the Hong Kong Society of Haematology (HKSH), Professor Pier Luigi Zinzani of the Department of Medical and Surgical Sciences, University of Bologna, Italy, shared real-world data on CAR T-cell therapies, including from his institution, and compared them within the class as well as against clinical trial setting.

Real-world experience with CAR T-cell treatment of B-cell lymphomas

22 Apr 2024

CAPTIVATE 5-year update: High PFS and OS rates with 1L ibrutinib + venetoclax in CLL/SLL

22 Apr 2024

Latest CAPTIVATE trial results, which were presented at the 65^th American Society of Hematology Annual Meeting and Exposition (ASH 2023) held in San Diego, California, US, show that the all-oral regimen of ibrutinib (a Bruton’s tyrosine kinase [BTK] inhibitor) plus venetoclax (a BCL-2 inhibitor) continues to provide high rates of progression-free survival (PFS) and overall survival (OS) at 5 years of follow-up when used as first-line treatment for chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), including in patients with high-risk disease features.

CAPTIVATE 5-year update: High PFS and OS rates with 1L ibrutinib + venetoclax in CLL/SLL

22 Apr 2024

Androgen receptor inhibitor plus chemotherapy and ADT in a patient with mHSPC and multiple comorbidities

22 Apr 2024 by

A 66-year-old male nonsmoker and nondrinker complained of generalized bone pain, poor appetite and abdominal discomfort in December 2022. He had hypertension, which was controlled with amlodipine/valsartan 5 mg/80 mg, and sleep apnoea. He was also a hepatitis B virus (HBV) carrier on maintenance entecavir. He had no family history of prostate cancer.

Androgen receptor inhibitor plus chemotherapy and ADT in a patient with mHSPC and multiple comorbidities

22 Apr 2024

Paediatric-onset immune-mediated inflammatory diseases raise mortality risk

22 Apr 2024

People with paediatric-onset immune-mediated inflammatory diseases (pIMID) have a roughly fourfold increased risk of death in adulthood, as suggested in a study.

Paediatric-onset immune-mediated inflammatory diseases raise mortality risk

22 Apr 2024

PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer

22 Apr 2024 by

Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.

PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer

22 Apr 2024

CPAP helps lower BP in patients with sleep apnoea

21 Apr 2024 by

Blood pressure (BP) slightly decreases in patients with obstructive sleep apnoea who undergo continuous positive airway pressure (CPAP) therapy, as seen in a study. Such effect is marginally higher in those with above-average apnea-hypopnea index (AHI).

CPAP helps lower BP in patients with sleep apnoea

21 Apr 2024

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Tirbanibulin 1% ointment proves safe and effective in patients with multiple actinic keratoses (AKs) treated in real-world settings, as shown in a study.

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Sleep apnoea implicated in cognitive impairment

20 Apr 2024 by

People with sleep apnoea tend to also show memory or cognitive symptoms, according to a study, suggesting an association between the sleep-related breathing disorder and cognitive function.

Sleep apnoea implicated in cognitive impairment

20 Apr 2024

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024 by

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

High potassium intake lowers CKD risk

High potassium intake lowers CKD risk

Real-world experience with CAR T-cell treatment of B-cell lymphomas

Real-world experience with CAR T-cell treatment of B-cell lymphomas

CAPTIVATE 5-year update: High PFS and OS rates with 1L ibrutinib + venetoclax in CLL/SLL

CAPTIVATE 5-year update: High PFS and OS rates with 1L ibrutinib + venetoclax in CLL/SLL

Androgen receptor inhibitor plus chemotherapy and ADT in a patient with mHSPC and multiple comorbidities

Androgen receptor inhibitor plus chemotherapy and ADT in a patient with mHSPC and multiple comorbidities

Paediatric-onset immune-mediated inflammatory diseases raise mortality risk

Paediatric-onset immune-mediated inflammatory diseases raise mortality risk

PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer

PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer

CPAP helps lower BP in patients with sleep apnoea

CPAP helps lower BP in patients with sleep apnoea

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Sleep apnoea implicated in cognitive impairment

Sleep apnoea implicated in cognitive impairment

Do GLP1 receptor agonists increase thyroid cancer risk?

Do GLP1 receptor agonists increase thyroid cancer risk?